Mackay Shields LLC Tg Therapeutics, Inc. Transaction History

Mackay Shields LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$32.5 - $48.96 $1.31 Million - $1.97 Million	-40,200 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$41.61 - $54.3 $1.42 Million - $1.85 Million	-34,100 Reduced 45.9%	40,200 $1.94 Million
Q4 2020 Feb 16, 2021	BUY	$25.27 - $54.9 $70,756 - $153,720	2,800 Added 3.92%	74,300 $3.87 Million
Q3 2020 Nov 04, 2020	BUY	$18.49 - $27.24 $234,822 - $345,948	12,700 Added 21.6%	71,500 $1.91 Million
Q2 2020 Jul 31, 2020	BUY	$8.9 - $21.84 $523,320 - $1.28 Million	58,800 New	58,800 $1.15 Million
Q4 2018 Feb 14, 2019	SELL	$3.44 - $5.76 $139,664 - $233,856	-40,600 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$5.15 - $14.0 $63,860 - $173,600	12,400 Added 43.97%	40,600 $227,000
Q2 2018 Aug 06, 2018	BUY	$12.5 - $15.0 $352,500 - $423,000	28,200 New	28,200 $371,000

339

88.5M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.88B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Mackay Shields LLC, based on Form 13F filings with the SEC.

Stay updated on Mackay Shields LLC with notifications on news.